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Tau hyperphosphorylation is thought to underlie tau-
opathy.Working in aDrosophila tauopathymodel ex-
pressing a human Tau mutant (hTauR406W, or Tau*),
we show that zinc contributes to the development of
Tau toxicity through two independent actions: by
increasing Tau phosphorylation and, more signifi-
cantly, by directly binding to Tau. Elimination of
zinc binding through amino acid substitution of Cys
residues has a minimal effect on phosphorylation
levels yet essentially eliminates Tau toxicity. The
toxicity of the zinc-binding-deficient mutant Tau*
(Tau*C2A) and overexpression of native Drosophila
Tau, also lacking the corresponding zinc-binding
Cys residues, are largely impervious to zinc concen-
tration. Importantly, restoration of zinc-binding abil-
ity to Tau* by introduction of a zinc-binding residue
(His) into the original Cys positions restores zinc-
responsive toxicities in proportion to zinc-binding
affinities. These results indicate zinc binding is a sub-
stantial contributor to tauopathy and have implica-
tions for therapy development.
INTRODUCTION
Tau protein aggregation is found in several types of neurode-
generative diseases collectively termed ‘‘tauopathy,’’ which
includes Alzheimer’s disease (AD), frontotemporal lobar degen-
eration chromosome 17, Pick’s disease, corticobasal degener-
ation, and the progressive supranuclear palsy (Brunden et al.,
2009; Iqbal et al., 2005). AD, the most common and severe
form of dementia, is alone an enormous burden to our ever-
aging society.
Tau is a microtubule-associated protein that can bind to mi-
crotubules and regulate their dynamics. Under normal physio-
logical conditions, Tau exhibits low levels of phosphorylation
(Bue´e et al., 2000); however, it is hyperphosphorylated in several
disease states. The abnormally hyperphosphorylated state of
Tau protein can cause it to dissociate from the microtubule
and aggregate into paired helical filaments (PHFs) (Kuret et al.,2005; Mazanetz and Fischer, 2007), leading to multiple down-
stream events and culminating in neuronal cell death (von Ber-
gen et al., 2005). Because a detailed mechanism for Tau toxicity
remains elusive, designing effective therapies for tauopathies
continues to be a challenge.
Transition metals, such as copper (Cu), iron (Fe), and zinc (Zn),
are indispensable for numerous fundamental biological pro-
cesses but are toxic when homeostasis is disrupted (Nelson,
1999). Increasing evidence indicates that they may also be
involved in human neurodegenerative diseases (Bush, 2003;
Lovell et al., 1998). It has been known for decades that abnor-
mally aggregated Tau proteins (PHFs) or so-called neurofibril-
lary tangles codeposit with several transition metals (Good
et al., 1992), and compromised metal homeostasis has been
demonstrated to be closely linked with the pathogenesis of
AD and tauopathy in vivo (Atwood et al., 2000; Bush, 2003;
Lang et al., 2012; Lovell et al., 1998). It was proposed that these
metals, in particular zinc, could induce Tau hyperphosphoryla-
tion (Egan˜a et al., 2003; Kim et al., 2011; Sun et al., 2012) by
activating kinases such as Raf/mitogen-activated protein kinase
kinase and inhibiting phosphatases like PP2A (Kim et al., 2011;
Sun et al., 2012; Xiong et al., 2013). Additionally, zinc has been
reported to interact with Tau directly in vitro (Mo et al., 2009),
although the in vivo significance of this direct interaction is not
known. Encouraging results from phase II clinical trials showed
that clioquinol (CQ), an old antibiotic that can act as a metal-
chelating agent, slowed AD development (Ritchie et al., 2003),
and recently, an improved derivative of CQ, PBT2, offered
even more promising results (Faux et al., 2010; Lannfelt et al.,
2008).
In a genetic screen to identify metal homeostasis genes that
might be involved in tauopathy, we discovered zinc transporters
ZIP1 and ZnT1 as modifiers using a previously established
Drosophila tauopathymodel (Wittmann et al., 2001). Subsequent
experiments revealed zinc affects Tau by two different means. It
can bind Tau directly, affecting Tau’s properties and behaviors in
a way that contributes to Tau toxicity. Also, through a mecha-
nism distinct from binding, zinc is also involved in increased
Tau phosphorylation. This latter effect appears to make a less
important contribution to Tau toxicity. We conclude that, in addi-
tion to hyperphosphorylation, which has already been linked to
tauopathies, direct zinc binding is another critical factor in Tau
toxicity.Cell Reports 8, 831–842, August 7, 2014 ª2014 The Authors 831
Figure 1. Genetic Alteration of Zinc Trans-
porter Expression Significantly Modulates
the Phenotypes of Tau Flies
(A) SEM photos of Tau* flies showing the modu-
lating effect of zinc transporters on the eyes. Elav-
Gal4 was used to drive Tau* expression in both
CNS and eyes. The scale bar represents 100 mm.
OE, overexpression.
(B) Modulating effect of zinc transporters on the
lifespans of Tau* flies. Elav-Gal4 was used to
express Tau* in the flies’ CNS. Log rank test:
Tau*/ZIP1-OE versus Tau*, p < 0.0001; Tau*/ZIP1-
RNAi versus Tau*, p < 0.0001; Tau*/ZnT1-OE
versus Tau*, p < 0.0001; Tau*/ZnT1-RNAi versus
Tau*, p < 0.01.
(C1 and C2) Hematoxylin and eosin (H&E)-stained
paraffin brain sections of these Tau* flies. Green
arrows indicate only some of the many degener-
ative vacuoles formed in the brain. The scale bar
represents 50 mm. (C2) is the quantification of (C1).
Data represent mean ± SEM; *p < 0.05; **p < 0.01.RESULTS
Zinc Reduction through Genetic or Dietary Measures
Can Partially Rescue Drosophila Tauopathy
To investigate possible connections between metal genes and
tauopathy, we set up a genetic screen to examine their interac-
tions via a Drosophila tauopathy model using the bipartite
upstream activating sequence (UAS)/Gal4 system. This fly tau-
opathy model uses hTauR406W (hereafter Tau* for short), a
mutant Tau found in some FTDP-17 patients (Reed et al.,
1997; Saito et al., 2002; van Swieten et al., 1999), and displays
increased toxicity over wild-type Tau (Wittmann et al., 2001). A
collection of overexpression or RNAi lines of genes likely relevant
to metal homeostasis (Cu, Zn, and Fe) (Table S1) were analyzed.
Elav-Gal4 was used to drive the expression in the CNS. Change
of eye roughness and lifespan were used as selection criteria in
the screening. Several zinc transporter genes, but not genes
related to other metals, were found to present consistent
rescuing or enhancing effects, suggesting they act as the mod-832 Cell Reports 8, 831–842, August 7, 2014 ª2014 The Authorsifiers of Drosophila tauopathy. Notably,
overexpression of dZnT1, a membrane
zinc exporter (Wang et al., 2009), or
inhibition of dZIP1, a membrane zinc
importer (Lang et al., 2012), could
partially suppress the rough-eye pheno-
type of Tau* flies (Figures 1A, Tau*/
ZnT1-OE and Tau*/ZIP1-RNAi, S1A, and
S1B), whereas the eye phenotype was
slightly enhanced by overexpression of
ZIP1 or inhibition of ZnT1 (Figures 1A,
Tau*/ZIP1-OE and Tau*/ZnT1-RNAi,
S1A, and S1B). In the absence of Tau*,
these genetic perturbations alone did
not produce noticeable eye phenotypes
(Figure S1C) or obvious survival disad-
vantage (Figure S1D). Similar effects of
the zinc transporters on Tau* toxicitywere also observed when Tau* expression was directed in the
eye using Gmr-Gal4 (Figure S1E). A quantification of head
transition metal levels by inductively coupled plasma-mass
spectrometry (ICP-MS) revealed zinc homeostasis was indeed
specifically perturbed by these genetic interventions (Fig-
ure S1F), and RT-PCR reactions were performed to confirm
the efficiencies of these genetic manipulations (Figure S1G).
Considerable improvements were observed in the lifespan
and brain degeneration. Overexpressing ZnT1 or knocking
down ZIP1 significantly elongated the lifespan of Tau* flies,
whereas overexpressing ZIP1 and, to a much-lesser extent,
knocking down ZnT1 shortened the lifespan (Figure 1B). Tau*
expression in Drosophila CNS causes vacuolization, reflecting
neuronal loss and degeneration. ZIP1 overexpression or ZnT1
RNAi exacerbated the vacuolization level, whereas ZnT1 overex-
pression or ZIP1 knockdown significantly reduced the number of
brain vacuoles (Figures 1C1 and 1C2). Therefore, genetically
perturbing zinc transporters could significantly affect the neuro-
degenerative phenotypes in fly brains.
Figure 2. Zinc Limitation Decreases Tau Phosphorylation
(A) Tau phosphorylation under different metal or CQ treatments. Antibodies
12E8, AT180, CP13, AT270, and PHF-1, as listed in the table, were used to
detect different phospho-epitopes of Tau*. 5A6 was used to indicate the total
Tau protein level, and 22C10 was used as an additional loading control.
(B) Genetic modulation of zinc transporter genes similarly alters Tau phos-
phorylation. Phosphorylation levels of different epitopes of Tau* protein were
detected by western blots. Results are reproducible in three independent
western blotting experiments, and only one is shown here.Having established that genetic modification of zinc trans-
porters could suppress the defects of Tau* flies, we explored
the possibility of tauopathy treatment by regulating dietary zinc
uptake. Dietary zinc levels were controlled by the addition of
ZnCl2 or CQ, a hydrophobic metal chelator (Adlard et al., 2008;
Li et al., 2010), to the fly food. Metal (Cu, Fe, Mn, and Zn) content
in these fly brains was measured by ICP-MS to confirm that the
dietary regulation really produced the anticipated metal level
changes (Figures S2A and S2B). Of note, the zinc-fed flies
showed marginally reduced iron levels, implying that there could
be a coregulation or interaction mechanism between zinc and
iron (Solomons, 1986). CQ also slightly increased copper con-
tent, but, as previously reported, most of the copper is appar-
ently unavailable for use so that, even when total cellular copper
is increased, a state of copper deficiency is still created by CQ (Li
et al., 2010).
Similar to what we observed as above in the genetic perturba-
tion experiments, zinc addition significantly enhanced the Tau*
toxicity (Figures S2C1 and S2C2), shortening the lifespan of
Tau* flies (Figure S3A), whereas CQ partially rescued Tau*
toxicity in Drosophila eyes (Figures S2C1 and S2C2) and elon-
gated the lifespan (Figure S3B). As a control, wild-type flies
(Elav-Gal4 > w) that were treated with the same levels of metals
showed no obvious lifespan changes (Figure S3C). The neurode-
generation process of Tau* flies was also accelerated by zinc in
the brain and eyes and partially mitigated by CQ (Figures S2D,
S3D1, and S3D2). A quantification of the degenerative vacuoles
formed per brain is shown in Figure S3D2.
Similar zinc effects were also observed in hypophosphory-
lated Tau mutants such as TauR406W/S262A/S356A (Tau*S2A)
and TauR406W/S202A (Tau*S202A; Nishimura et al., 2004; Fig-
ures S3E and S3F). Whereas these hypophosphorylated Tau*mutants have greatly reduced toxicity and longer lifespans, their
lifespans could still be significantly shortened by zinc and
rescued by CQ in the case of Tau*S202A flies (Tau*S202A has
stronger toxicity than Tau*S2A but less than Tau*). These results
from genetic and dietary rescue studies indicate that changes in
zinc homeostasis can have a partial but significant influence on
the overall progression of tauopathy in vivo.
Zinc Increases Tau Phosphorylation Level
We next investigated how zinc could affect Tau toxicity. In AD
and other tauopathies, accumulation of abnormally phosphory-
lated Tau is a hallmark of these diseases and is involved in fibril
formation and neuron loss (Alonso et al., 1996, 2004; Herna´ndez
and Avila, 2007; Necula and Kuret, 2004). Hyperphosphoryla-
tions at serine and proline sites or threonine and proline sites
have been found in disease samples (Yen et al., 1995), and
several studies have suggested possible connections between
zinc and Tau hyperphosphorylation (Boom et al., 2009; Sun
et al., 2012). We thus analyzed Tau phosphorylation with a set
of phospho-specific antibodies such as AT180, CP13, PHF-1,
12E8, and AT270, which could recognize different Tau phos-
pho-epitopes of Tau (Dias-Santagata et al., 2007; Nishimura
et al., 2004; Wittmann et al., 2001) (Figure 2A, table). Western
blot results show that the AT180, CP13, and PHF-1 signals
were reduced after CQ treatment and increased after zinc treat-
ment (Figure 2A, image), three phosphorylation sites that have
been previously demonstrated as important contributors to
Tau toxicity.
When we genetically perturbed zinc homeostasis in the brain,
similar changes of phosphorylation levels were also observed at
these three sites (Figure 2B). Specifically, zinc importer ZIP1
RNAi or zinc exporter ZnT1 overexpression resulted in a reduc-
tion of phosphorylation at sites recognized by CP-13, AT180,
and PHF-1 antibodies, and ZIP1 overexpression or ZnT1 RNAi
gave exactly the opposite results.
We conclude that zinc could indeed affect Tau phosphoryla-
tion in the fly tauopathy model, possibly due to its effects on
Tau phosphorylation pathways (Boom et al., 2009; Sun et al.,
2012). But whether this phosphorylation alteration solely
explains the effect of zinc on Tau toxicity still remained
unanswered.
Zinc Directly Induces Tau Protein Aggregation In Vitro
Because zinc can bind to Tau in vitro via two Cys residues (C291
and C322; Mo et al., 2009), we wondered if zinc binding played a
role in tauopathy. We used circular dichroism (CD) spectroscopy
to test whether this binding could induce a secondary structure
change in Tau protein. CD spectra of Tau* proteins coincubated
with different metals (Cu, Fe, and Zn) did show that zinc acted as
a strong promoter of Tau* conformational change (Figure 3A): the
negative peak at 200 nmwas reduced significantly whereas a red
shift of the peak was also observed with zinc, indicating a struc-
tural change from the random coil. Although copper and iron also
exhibited slight effects on Tau conformation at a higher concen-
tration as reported previously (Ma et al., 2005, 2006), these
metals failed to show any obvious effects at the lower concentra-
tion (5 mM) (Figure 3A). On the other hand, metal chelator CQ
could effectively reverse the conformational change inducedCell Reports 8, 831–842, August 7, 2014 ª2014 The Authors 833
Figure 3. Zinc Interacts with Tau and Induces Tau Conformation Change and Aggregation In Vitro
(A) Circular dichroism (CD) spectra of Tau* proteins coincubated with different metals. 5 mM copper (Cu), 5 mM iron (Fe), and 5 mM zinc (Zn) were used. Protein
concentration: 70 mg/ml.
(B) CD spectra of Tau* proteins incubated with Zn and CQ. 5 mM Zn was used to induce conformation change, and 5 or 10 mM CQ was used to reverse the zinc
effects. Protein concentration: 70 mg/ml.
(C and D) CD spectra of Tau*S202A and Tau*S2A incubated with different metals at the ‘‘low concentration’’ (5 mM). Protein concentration: Tau*S2A: 70 mg/ml;
Tau*S202A: 90 mg/ml.
(legend continued on next page)
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by zinc, returning Tau to its natural conformation (Figure 3B), as
indicated by the observed changes in the 200 nm negative peak.
This reversible process of CD changes suggested a potential
physical binding between zinc and Tau. Conformations of hypo-
phosphorylated Tau mutants such as Tau*S2A and Tau*S202A
(Nishimura et al., 2004) could similarly be affected by zinc at
the low concentration (5 mM; Figures 3C and 3D).
We next tested whether even lower zinc levels could induce
Tau conformation change. Zinc concentrations as low as 0.25
or 0.5 mM, comparable to physiological zinc levels (Mocchegiani
et al., 2005), could still induce significant changes in Tau* confor-
mation (Figure 3E). The stronger promoting effect of zinc on Tau
fibrillization was also confirmed by the Thioflavin T (Th-T) fluores-
cence assay (Figure 3F), wherein Th-T displayed an increased
fluorescence when bound to aggregated Tau. The presence of
heparin further enhanced the Th-T signals in general.
We additionally used transmission electron microscope (TEM)
to visualize possible zinc-induced polymerizations of Tau pro-
teins. Before incubation with metal ions, some background sig-
nals could sometimes be observed, likely resulting from small
amounts of oligomers formed during protein preparation (Fig-
ure 3G). After metal incubation, Tau* proteins could be seen to
form small aggregates in almost all samples (Figure 3G, green
arrowheads). However, longer filament-like structures could
only be found in the sample with zinc (Figure 3G, in Zn panel,
green arrow). Zinc therefore, at least in vitro, could directly
induce Tau* protein conformation change and promote its
polymerization.
Removal of Zinc Binding Effectively Eliminates Tau
Toxicity
Because zinc is an essential nutritional element, removing it
entirely from a cell or organism is unfeasible. Dramatic loss, as
well as increase, of intracellular zinc inevitably results in cell
death. To better demonstrate in vivo whether the direct zinc
binding to Tau is functionally relevant, site-specific mutagenesis
was utilized to replace potential zinc-binding sites (Mo et al.,
2009) (Figure 4A, C291A and C322A, red sites) in the Tau* pro-
tein. Single mutants C291A and C322A and double mutant
C291A/C322A (Tau*C2A for short) were generated and com-
pared with Tau*S2A (Figure 4A, S262A and S356A, green
sites) or Tau* itself for toxicities. C291A andC322A single-substi-
tution mutants displayed almost identical phenotypes as
Tau*C2A double mutant (Figure S4). Here, we will present
only Tau*C2A as examples. As a control, we showed that the
mutant Tau*C2A exhibited a similar CD profile as that of Tau*
(Figure S5A), suggesting little conformation change results
from these amino acid replacements. Immunostaining also re-
vealed that Tau*C2A colocalizes with microtubules in the
Drosophila motor neuron axon and muscle, similar to Tau* and(E) CD spectra of Tau* proteins under even lower Zn concentrations. Note lower
reaction systems were dialyzed to remove zinc and concentrated by polyoxyeth
(F) Th-T fluorescence was used to detect Tau polymerization. Tau* proteins were
absence of 1 mmol/ml heparin as a polymerization inducer. Shown here are fluore
**p < 0.01.
(G) TEM images of Tau* proteins coincubated with different metals. Arrowheads in
by Tau aggregations. Protein concentration: Tau*: 70 mg/ml. The scale bar repreTau*S2A (Figures S5B1 and S5B2). Further, coimmunoprecipita-
tion confirmed all three proteins (Tau*, Tau*C2A, and Tau*S2A)
are able to bind to the microtubule components, again suggest-
ing normal functions are retained in Tau*C2A (Figure S5C). How-
ever, in vitro CD spectra analysis indicated Tau*C2A is no longer
able to bind to zinc (Figure 4B), in contrast to Tau* (Figure 4C) and
Tau*S2A (Figure 4D).
Ectopically expressed Tau*C2A and Tau*S2A displayed
dramatically reduced levels of toxicity in fly eyes in compari-
son to Tau* (Figures 4E, S5D, and S5E). In the lifespan assays,
we also observed similarly prolonged survival of Tau*C2A
(mean lifespan about 60 days) and Tau*S2A flies (mean life-
span about 63 days), when compared with Tau flies (mean life-
span about 30 days) (Figure 4F). In order to rule out differences
in protein expression, we determined that all three chosen
lines express comparable amounts of target proteins. Brain
sections from Tau*, Tau*C2A, and Tau*S2A flies were addition-
ally examined for vacuole formations. Far fewer vacuoles were
found in Tau*C2A and Tau*S2A flies brains, indicating a great
reduction of Tau*-induced neurodegeneration (Figures 4G1
and 4G2).
Loss of Zinc Binding Confers Tau Inertness to Zinc
Changes
If loss of toxicity for Tau*C2A is the result of loss of zinc binding,
and for Tau*S2A from phosphorylation reduction, we expect the
zinc responses of Tau*C2A, Tau*S2A, and Tau* flies to be
different. Indeed, unlike that of Tau* and Tau*S2A flies, zinc could
not appreciably affect the lifespan of Tau*C2A flies (Figure 5A).
However, for similarly nontoxic Tau*S2A, which is able to bind
zinc, zinc-responsiveness was still apparent (Figure 5A). Paraffin
brain sections also revealed that zinc could not influence the
toxicity of Tau*C2A: when treated with zinc, the neurodegenera-
tion in Tau*C2A flies did not noticeably worsen as measured
by the number of vacuoles formed in the brains (Figures 5B1
and 5B2).
The effect of zinc on these Tau* variants was reproduced with
in vitro binding assays. When incubated with zinc, both Tau*S2A
and Tau* formed aggregates whereas Tau*C2A failed to do so
(Figure 5C, arrowheads for small aggregations and arrows for
filament-like aggregations). Polymerization of these Tau* vari-
ants was also examined in vivo. Zinc treatment significantly
increased the amount of Tau in the insoluble fraction for both
Tau* and Tau*S2A (Figure 5D) but without obvious effect on
Tau*C2A (Figure 5D).
Interestingly, normal Drosophila Tau (dTau) lacks Cys (Fig-
ure S6A). Therefore, it is likely that the zinc-binding Cys residues
may not be necessary for normal Tau functions, consistent with
our CD andmicrotubule binding results as reported above. How-
ever, it would be worthwhile to test whether the toxicity fromconcentrations of Tau* protein (40 mg/ml) and zinc (0.25 mM) were used. The
ylene before measuring their CD spectra.
incubated with 5 mMZn, 5 mMCu, and 5 mM Fe, respectively, in the presence or
scence signal changes after 7 days of incubation. Data represent mean ± SEM.
dicate possible Tau oligomers, and big arrows indicate small filaments formed
sents 200 nm.
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Figure 4. Zinc Binding Is Essential for Tau
Toxicity
(A) A sketch of Tau* protein showing all the
relevant residues described in this work. The two
zinc-binding Cys sites (Cys291 and Cys322) are
represented in red, whereas the two phosphory-
lation sites (Ser262 and Ser356) in green. For
simplicity, C2A was used to indicate Tau* pro-
tein containing Cys291Ala and Cys322Ala sub-
stitutions and S2A Tau* protein with Ser262Ala
and Ser356Ala changes.
(B–D) CD spectra of Tau* (protein concentra-
tion: 8 mg/ml), Tau*C2A (protein concentration:
8 mg/ml), and Tau*S2A (protein concentration:
10 mg/ml) proteins coincubatedwith zinc. Arrows
mark the approximate 200 nm peak. Apparent
zinc-induced conformation changes appeared in
Tau* and Tau*S2A, but not Tau*C2A.
(E) Tau*C2A flies have much less affected eyes.
Shown are eye scanning electron microscopy
images of Tau*, Tau*S2A, and Tau*C2A flies.Gmr-
Gal4 was used to drive the eye expression of Tau.
The scale bar represents 100 mm.
(F) Tau*C2A flies have a much longer lifespan
(comparable to that of Tau*S2A flies) than Tau*.
Elav-Gal4 was used to drive Tau* expression in
CNS. The difference between Tau* and Tau*C2A
or Tau*S2A lifespans was significant, p < 0.0001
(log rank test).
(G1 and G2) H&E-stained paraffin brain sections of
Tau*, Tau*C2A, and Tau*S2A flies. The scale bar
represents 50 mm. Green arrowheads indicate
some of the degenerated vacuoles. Statistical
analysis of the results is shown in G2. Data
represent mean ± SEM; **p < 0.05.dTau overexpression is responsive to zinc level change. Again,
as we observed with Tau*C2A, dTau toxicity is largely insulated
from zinc level alterations (Figure S6B).
Taken together, these results indicate loss of zinc binding
effectively suppresses Tau toxicity from deleterious zinc-modu-
lating effects.
Restoration of Zinc Binding to Tau Correlatively
Restores Its Toxicity and Zinc Responsiveness
One caveat associated with mutating Cys to Ala in Tau* is that, in
addition to loss of zinc binding, the amino acid substitution might
also affect other biological aspects of Tau. To address this
question, we made additional Tau* mutants: Tau*C291H and
Tau*C2H (C291H and C322H). We reasoned that, if loss of zinc
binding is indeed the sole factor attributed to the decrease in
toxicity, Tau*C291H (relative to Tau*C291A) or Tau*C2H (relative
to Tau*C2A) may regain zinc-binding ability as histidine residues836 Cell Reports 8, 831–842, August 7, 2014 ª2014 The Authorsare also often utilized by proteins to bind
zinc. If this were the case, we would
expect these mutants to restore zinc-
responsive toxicity in Tau. When assayed
by fluorescence quenching, the two Tau*
mutants exhibited better zinc response
than the non-zinc binding Tau*C2A,though neither aswell as Tau* itself. Tau*C2H, in particular, binds
zinc significantly more weakly (Figure 6A). Both exhibited very
little toxicity under normal conditions when assayed by longevity
(Figures 6B and 6C). However, when the zinc levels were
increased, Tau*C291H and to a lesser extent Tau*C2H regained
toxicity (Figures 6B and 6C). In fact, in the survival assay,
elevated zinc concentrations caused Tau*C291H to exhibit a
level of toxicity nearly comparable to that of Tau* under nonele-
vated zinc concentrations. Brain sectioning revealed similar
results (Figures 6D1 and 6D2). These results are in contrast
with what was observed with C to A changes, which were rela-
tively insulated from zinc alterations. The correlation between
Tau* toxicity and zinc-binding ability, together with the Tau*C2A
and dTau results, provide strong support for our model that
the toxicity loss associated with mutating cysteine residues
results from an attenuation or loss in zinc binding, but not other
factors.
Figure 5. Substitution of Zinc Binding
Residues Essentially Eliminates the Zinc
Responsiveness of Tau Toxicity
(A) Lifespans of Tau*C2A flies are essentially inert
to zinc changes. Shown here are Tau*, Tau*S2A,
and Tau*C2A flies under zinc treatment. Elav-Gal4
was used to express proteins in the CNS. Tau*-NF
versus Tau*-Zn, p < 0.0001; Tau*S2A-NF versus
Tau*S2A-Zn, p < 0.0001; Tau*C2A-NF versus
Tau*C2A-Zn, pz 0.05. NF, normal food.
(B1 and B2) Brain degeneration is not significantly
affected by zinc treatment in Tau*C2A flies. Shown
here are H&E-stained paraffin brain sections of
Tau*, Tau*C2A, and Tau*S2A flies under zinc
treatment. The scale bar represents 50 mm. Green
arrowheads indicate some of the many degen-
erated vacuoles. A quantitative and statistical
analysis of B1 is shown in B2. Data represent
mean ± SEM and were compared with NF group
within each genotype. *p < 0.05; **p < 0.01. n.s.,
p > 0.05, not significant.
(C) Tau*C2A does not respond to zinc incubation
in vitro. TEM images of Tau*, Tau*S2A, and
Tau*C2A proteins coincubated with zinc are pre-
sented. The scale bar represents 200 nm. The
concentrations of Tau*, Tau*S2A, and Tau*C2A
were adjusted to 50 mg/ml before the metal
incubation.
(D) Zinc treatment increases the insoluble species
of Tau protein in vivo. Insoluble Tau fractions were
extracted from fly heads using the extraction
buffer containing 1% SDS and detected by Tau5
antibody. Actin was used as a control to show
comparable loadings among samples.Zinc Binding and Phosphorylation Are Two Independent
Events for Tau
If zinc binding is essential for themanifestation of Tau toxicity, we
asked if zinc binding might increase Tau phosphorylation, result-
ing in elevated toxicity, whereas loss of zinc binding could
reduce phosphorylation. If this were the case, our zinc-binding
mutant Tau*C2A would show lower levels of phosphorylation.
To explore this possibility, we examined the phosphorylation
levels of Tau*C2A, Tau*S2A, and Tau* proteins by immunoblot-
ting. To our surprise, Tau*C2A maintained comparable levels of
phosphorylation with that of Tau*. In fact, both Tau* and Tau*C2A
showed much higher phosphorylation levels than Tau*S2A (Fig-
ure 7A), whose loss of toxicity is attributed to phosphorylation
reduction (Nishimura et al., 2004). Likewise, we also observed
comparable phosphorylation among Tau*, Tau*C291H, and
Tau*C2H (Figure 7B). These results indicate that the reduced
toxicity observed in Tau*C2A is not due to Tau phosphorylation
changes; instead, it is caused by the abolished zinc binding
per se.
As previously demonstrated, Tau*C2A toxicity is relatively
insulated from changes in zinc concentration. However, when
we probed the phosphorylation levels of Tau*C2A in vivo, we
found that, similar to Tau*, it still displayed the zinc-induced in-
crease in phosphorylation at several phospho-epitopes (Fig-
ure 7C), confirming that zinc binding to Tau and zinc’s enhancingeffect on Tau phosphorylation are indeed two distinct and sepa-
rable actions. Phosphorylation in Tau*S2A is also affected by
zinc exposure (Figure 7C), indicating Tau phosphorylation is at
least partially independent of PAR-1, because phosphorylation
of S2A is not attributed to PAR-1 (Nishimura et al., 2004). Consis-
tently, previous findings indicate zinc regulates Tau phosphory-
lation indirectly, likely through affecting several kinase pathways,
like Erk (Kim et al., 2011), p70S6K (An et al., 2005), and phospha-
tase PP2A (Sun et al., 2012; Xiong et al., 2013). In summary, our
results have uncoupled zinc binding and zinc-induced phos-
phorylation as two independent factors in Tau toxicity.
DISCUSSION
Zinc contributes to Tau’s toxicity by two independent ways.
First, zinc indirectly affects Tau phosphorylation likely through
the action of kinase or phosphatase pathways. In another,
more important aspect, it directly binds to Tau and serves a crit-
ical role for Tau toxicity. By mutating zinc-binding residues of
Tau, we were able to distinguish between zinc’s two modes of
action. Amazingly, removal of zinc binding almost completely
abolishes Tau toxicity, suggesting that zinc binding and hyper-
phosphorylation equally contribute to tauopathy. We propose
that appreciable Tau toxicity requires both the presence of hy-
perphosphorylation and zinc binding (Figure S7).Cell Reports 8, 831–842, August 7, 2014 ª2014 The Authors 837
Figure 6. Restoration of Zinc Binding to
Tau Regains Correlatively Its Zinc Respon-
siveness
(A) Various forms of Tau* upon zinc binding as
detected by intrinsic fluorescence quenching.
Fluorescence excited at 280 nm was measured
after 5 min equilibration.
(B) Lifespan of Tau*C291H flies versus zinc. Zinc
supplementation can enhance Tau*C291H toxicity
to a level approaching that of Tau under normal
diets. Elav-Gal4was used to drive Tau expression.
Tau*-NF versus Tau*-Zn, p < 0.0001; Tau*C291H-
NF versus Tau*C291H-Zn, p < 0.0001.
(C) Lifespan of Tau*C2H flies. Comparing with that
of Tau*C2A, the lifespan of Tau*C2H flies can
still be affected by zinc. Tau*C2H-NF versus
Tau*C2H-Zn, p < 0.01.
(D1 and D2) Brain degeneration was also affected
by zinc treatment in Tau*C291H and Tau*C2H
flies. Shown here are H&E-stained paraffin brain
sections of Tau*, Tau*C291H, and Tau*C2H flies
under zinc treatment. A quantitative and statistical
analysis is shown in D2. The scale bar represents
50 mm. Green arrowheads indicate only some of
the many degenerated vacuoles. Data represent
mean ± SEM; *p < 0.05; **p < 0.01.Previously, zinc’s effect on Tau was assumed to be auxiliary
(Boom et al., 2009; Budimir, 2011; Greenough et al., 2013). The
lack of in vivo evidence and the indispensability of zinc for normal
cellular functions made evaluating zinc’s role in tauopathy a
challenge. Through our set of carefully designed experiments,
we were able to clearly separate the phosphorylation effect
and zinc-binding effect and establish zinc’s key role in the path-
ogenesis of tauopathy. The effect of zinc binding is otherwise
hard to discern due to the concomitant effect of zinc on Tau
phosphorylation and because zinc modulation, by genetic or
chemical measures,must be limited to avoid causing detrimental
effects in vivo.
Although our results show that zinc has an effect on Tau
hyperphosphorylation pathways, this effect appears to be less
important to Tau toxicity than zinc binding directly to Tau. This
conclusion is clearly supported by results from the reduced
toxicity of the Tau*C2A mutant, which cannot bind zinc but ex-
hibits normal zinc-responsive phosphorylation. Despite zinc-
responsive phosphorylation changes, Tau*C2A phenotypes are
not much affected by zinc level alterations. In comparison,
Tau*S2A, which shows reduced levels of phosphorylation but
maintains its ability to bind zinc, shows greater toxicity in
response to increases in zinc.838 Cell Reports 8, 831–842, August 7, 2014 ª2014 The AuthorsPrevious in vitro studies show that the
two Cys residues altered in Tau*C2A
may be also involved in intramolecular
and intermolecular Cys-Cys crosslink-
ing actions. Specifically, substitution of
C291A suppresses intracellular disulfide
bond formation and leads to elevated
intermolecular crosslinking and toxicity,
whereas C322A diminishes toxicity(Schweers et al., 1995). According to the crosslinking model,
C291A should bemore toxic than even the normal Tau. However,
in our hands, both C291A and C322A presented little toxicity
in vivo, suggesting the change of crosslinking cannot explain
the loss of toxicity here. To further show that it is indeed zinc
binding that contributes to Tau toxicity, we further made
Tau*C291H and Tau*C2H mutants. These two mutants should
not have the proposed crosslinking ability as conferred by Cys
residues in Tau*; however, they displayed zinc-responsive
toxicity as Tau*, in accordance with their zinc-binding abilities.
Several metals (copper, iron, and zinc) possess the ability to
bind Tau peptides and induce aggregations in vitro (Boom
et al., 2009; Ma et al., 2005, 2006; Mo et al., 2009; Yamamoto
et al., 2002), yet no genetic evidence has ever been given to sub-
stantiate the functional relevance of these interactions in vivo. In
this study, we used a Drosophila model to verify these interac-
tions between metals and tauopathy. Only zinc among the three
transition metals listed showed a toxicity-enhancing effect
in vivo. It is possible that the other metals bind Tau with less
affinity and the internal cellular environment does not provide
high enough levels of these ions.
Religa et al. (2006) reported that elevated cortical zinc is a
feature of advanced AD, correlating with increased cognitive
Figure 7. Zinc Binding to Tau and Its Effect on Tau Phosphorylation
Are Two Independent Events
(A) Tau*C2A undergoes similar phosphorylation as Tau*. Shown are phos-
phorylation levels of Tau*, Tau*S2A, and Tau*C2A proteins as detected by
western blots.
(B) Tau*C2H and Tau*C291H also undergo similar phosphorylation as Tau*.
Shown are phosphorylation levels of Tau*, Tau*C2A, and Tau*C291H proteins.
(C) Phosphorylation of Tau*C2A is similarly affected by zinc. Elav-Gal4 was
used to express the proteins in CNS. Tau5 was used to indicate the total Tau
level, and actin was used as an additional loading control.deterioration and highest plaque burden. We found Ab expres-
sion itself is sufficient to induce zinc accumulation in the fly
head (Lang et al., 2012), whereas little overall increase was
observed in tauopathy flies (data not shown). Therefore, in AD,
a combination of Ab plaque and tauopathy, with the increased
zinc level as a result of Ab accumulation, could accelerate late
Tau toxicity development, leading to advanced AD.
The apparent zinc involvement in both tauopathy and Ab-
generated toxicity (Cherny et al., 2001; Lang et al., 2012; Suh
et al., 2000) has led researchers to question whether zinc
reduction would be even more effective in AD treatment.
Indeed, chelating therapy at the organismal level has shown
some promising signs in AD clinical trials (Budimir, 2011;
Duce and Bush, 2010). Our use of CQ also significantly
improved the pathological findings of Tau flies. However,
because zinc is such an important cofactor ubiquitously
involved in many fundamental biological reactions, reduction
of zinc to a critical level may substantially affect the corre-
sponding processes and become deleterious to organism’s
survival. Indeed, interfering with the expression of some of
the zinc transporters can even lead to the death of the organ-
ism. Thus, although zinc reduction is effective in mitigating Tau
toxicity, zinc’s full role in tauopathy may not be fully uncovered
due to limited physiologically allowable zinc reduction. In other
words, the reduction of Tau toxicity is significantly less dra-
matic through zinc reduction than zinc binding removal, sug-gesting Tau’s zinc binding is with relatively high affinity and
zinc-Tau binding is still prevalent even under reduced zinc
conditions. Compared to the organism-wide zinc reduction
through dietary uptake limitation, more stringent restriction of
zinc in only pathologically affected regions is worth consider-
ation. In addition, a much more effective therapy would involve
specifically perturbing the interaction between Tau and zinc,
for example, with a small molecule inhibitor that binds to
Tau’s zinc-binding region. Our current study is an important
step forward toward understanding the etiology of tauopathy
and may aid in the future design of more-effective treatment
strategies.
EXPERIMENTAL PROCEDURES
Drosophila Stocks and Genetics
General fly stocks used in this study were obtained from the Bloomington
Drosophila Stock Center. UAS-TauR406W (UAS-Tau*), UAS-TauR406W
(S202A) (UAS-Tau*S202A), and UAS-TauR406W(S2A) (UAS-Tau*S2A) flies
were as previously described (Nishimura et al., 2004). For all the physiological
and biochemical assays, Gmr-Gal4 flies were crossed with UAS-Tau* flies to
ectopically express Tau* in the eyes, and Elav-Gal4 flies were crossed with
UAS-Tau* flies to express Tau* in the CNS. Flies were raised in standard
corn meal food under 25(±1)C unless noted.
Chemical Treatment and Lifespan Recording
For lifespan recordings, newly eclosed adults were raised on standard corn
media with or without metal or other chemical supplements. In metal treatment
experiments, a final concentration of 1mMZnCl2, 1mMFAC (ammonium ferric
citrate), or 0.25 mM CuCl2 was added to the diet; in CQ treatment, flies were
fed with 0.5 mM CQ diluted from a stock solution dissolved in DMSO, and in
this case, 1% DMSO was used as the corresponding control. Lifespans
were recorded at 25C. At least 100 flies were used for each individual
experiment.
Site-Directed Mutagenesis and Fly Transformation
pUAST vector containing human Tau(R406W) (Tau*) was used as the template
to generate various Tau mutants via site-directed mutagenesis. Constructs
were sequence confirmed and transformed into fly w1118(w) background.
Multiple transgenic lines were obtained and inserts confirmed by genomic
PCR. Protein expression levels were determined by western blot with Tau5
antibodies (mouse 1:1,500; Invitrogen).
Immunoblotting
To analyze phosphorylation levels of Tau proteins, adult fly heads were ho-
mogenized in the lysis buffer as described (Nishimura et al., 2004). Protein ex-
tracts were separated by 12% SDS-PAGE. The samples on polyvinylidene
fluoride membranes were then incubated with antibodies at the following dilu-
tions: 5A6 (mouse 1:2,000), PHF-1 (mouse 1:1,500), CP13 (rabbit 1:2,000),
AT270 (mouse 1:1,500), AT180 (rabbit 1:1,500), 12E8 (mouse 1:2,500),
22C10 (mouse 1:500), Tau5 (mouse 1:1,500), and actin (mouse 1:1,500).
PHF-1 and 5A6 were from the Hybridoma Bank (University of Iowa), and the
other antibodies were derived as described (Nishimura et al., 2004) or pur-
chased from Invitrogen. Secondary antibodies were peroxidase-labeled anti-
mouse immunoglobulin G (IgG), or anti-rabbit IgG, and signals were developed
by enhanced chemiluminescence (Pierce). Nonionic detergent soluble and
insoluble Tau fractions were prepared following a previously described
method (Khurana et al., 2010). Equivalent amounts of soluble and insoluble
proteins from different groups were loaded for the western blotting and probed
by Tau5 (mouse 1:1,500) and actin (mouse 1:1,500) antibodies.
Protein Expression, Purification, and Circular Dichroism Spectra
Measurement
Human Tau(R406W) 0N4R form of Tau*, Tau*C2A, Tau*C2H, Tau*C291H, and
Tau*S2A coding regions were cloned into pMXB10 (New England Biolabs)Cell Reports 8, 831–842, August 7, 2014 ª2014 The Authors 839
vector. Proteins were purified by chitin beads (NEB) as described (Venter et al.,
2011; Wang et al., 2010) and concentrations measured by the BCA kit (Thermo
Scientific). In the CD assay, proteins were incubated with zinc or other metals
at 37C in 0.01 M PBS (pH = 7.4) buffer containing 1 mM dithiothreitol (DTT).
CD spectra were measured in the far ultraviolet region (190–260 nm) and re-
corded by the Jasco J-715 Spectropolarimeter.
Th-T-Binding Assay
To analyze metal-induced Tau polymerization, freshly prepared 0.6 mmol Tau*
protein (about 24 mg) was incubated with or without metals (5 mMCu, Fe, or Zn)
in 200 ml 20 mM Tris-HCl buffer containing 1 mM DTT (pH = 7.4) for 1 week.
Th-T (Sigma-Aldrich) solution was freshly prepared, filtered, and then added
to a final 20 mM concentration. Fluorescence of Th-T was recorded at
440 nm excitation and 480 nm emission by the luminescence spectrometer
(SYNERGY4; Gene Company; Mo et al., 2009).
Fluorescence Quenching Assay
We assayed 0.05 mg purified protein in 500 ml buffer (0.01 M PBS; 1 mM DTT
[pH = 7.4]) for changes in fluorescence intensity. Zinc was added stepwise,
and emission readings were collected. Fluorescence was monitored at
348 nm following excitation at 280 nm using a F4500 Fluorescence Spec-
trometer (Zundel et al., 1998).
Histology
For paraffin sections, fly heads were fixed in Carnoy fixation solution (ethanol:
chloroform:acetic acid = 6:3:1) for 4 hr at the room temperature, then dehy-
drated sequentially by 100% ethanol for 30 min twice, dry ethanol (100%
ethanol dried with desiccant) and methyl benzoate each for 1 hr, and stepwise
embedded in melted paraffin. The paraffin-embedded fly heads were
sectioned into 8 mm continuous sections. Hematoxylin-eosin (ZSGB-BIO)
staining was used to facilitate the observation of the vacuoles in the brain
samples.
TEM and Scanning Electron Microscopy
Freshly prepared Tau proteins were incubated overnight with or without
metals at 37C in 0.01 M PBS buffer containing 1 mM DTT (pH = 7.4).
Uranyl-acetate-negative staining was performed to facilitate subsequent
TEM observations. Aggregate formation was examined by transmission elec-
tron microscope (H-7650B). Scanning electron microscopy analysis of fly
eyes was performed as described previously (Chatterjee et al., 2009) with
FEI Quanta 200.
Metal Content Analysis
Sixty adult heads were collected, and metal contents were assayed using the
ICP-MS XII (Thermo Electron) as described previously (Tang and Zhou, 2013).
Data were normalized with weights of the samples.
Statistics
Data are presented as mean ± SEM. Differences among groups were
analyzed by the IBM SPSS v13.0 with Student’s t (comparison of two groups)
or ANOVA test (three groups or more). *p < 0.05; **p < 0.01. Differences be-
tween lifespans were analyzed by the log rank method using the GraphPad
Prism 5 software, *p < 0.05; **p < 0.01; ***p < 0.0001; not significant (n.s.):
p > 0.05.
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